1-4 of 4
Emilie Lemieux-Blanchard, BSc,MD
Close
Sort by
Journal Articles

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Claudie Lavoie-Gagnon, MD, Jonathan St-Gelais, MD, Jean-Philippe Adam, BPharm, MSc, BCPS, BCOP, Daniel Viens, MD FRCPC, Félixe Gagné, Pharm.D., MSc, Yann Décarie, MSc, Emilie Lemieux-Blanchard, BSc,MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1870.
https://doi.org/10.1182/blood.V130.Suppl_1.1870.1870
Published: 2017
Journal Articles

Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada

Nathalie Marcotte, B.Pharm, MSc, Marie-Claude Michel, Louise Deschenes, MD, Nathalie Letarte, BPharm, MSc, BCOP, Daniel Froment, MD, Emilie Lemieux-Blanchard, BSc,MD FRCPC, France Varin, Ghislain Bérard, Paul Farand, MD, Élaine Pelletier, Pierre Gaudreault, MD, Chantal Guévremont, Raghu Rajan, MD, Michael Sebag
Journal: Blood
Blood (2015) 126 (23): 5573.
https://doi.org/10.1182/blood.V126.23.5573.5573
Published: 2015
Journal Articles

Targeting Patient at High Risk of Thrombocytopenia and Neutropenia with Cybord, Vel-Dex and VMP: Time to Decrease the Number of Blood Tests ?

Jean-Philippe Adam, B. Pharm., M.Sc., BCPS, Emilie Lemieux-Blanchard, BSc,MD FRCPC, Bernard Lemieux, MD FRCP, Nathalie Letarte, BPharm, MSc, BCOP
Journal: Blood
Blood (2014) 124 (21): 1295.
https://doi.org/10.1182/blood.V124.21.1295.1295
Published: 2014
Journal Articles

First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital

Jean-Philippe Adam, B. Pharm., M.Sc., Emilie Lemieux-Blanchard, BSc, MD, FOnline-OnlyPC, Bernard Lemieux, MD, FOnline-OnlyP, Nathalie Letarte, BPharm, MSc, BCOP
Journal: Blood
Blood (2013) 122 (21): 5610.
https://doi.org/10.1182/blood.V122.21.5610.5610
Published: 2013